US Bancorp
STLN

US Bancorp’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

US Bancorp’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295 Buy
+96
New +$294 ﹤0.01% 4061

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

US Bancorp's STLN Position: Q1 2026 in Review

US Bancorp opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 96 shares worth $295. The stake represents ﹤0.01% of the portfolio and ranks #4061 among its holdings.

115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • US Bancorp held 96 shares of Starling Oncology Institute, Inc. Common Stock worth $295 as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new US Bancorp position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4061 holding.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.